Background: Polycystic ovary syndrome (PCOS) is a multifactorial, heterogeneous, endocrine-metabolic disorder that commonly affects women at their reproductive age. PCOS is a complex syndrome characterized by chronic oligo-or anovulation, menstrual irregularities, hyperandrogenism, infertility, and polycystic ovarian morphologic features. The aim of the work WAS to evaluate the effect of vitamin D3 supplementation on insulin resistance, and visceral fat thickness in vitamin D3 deficient women with polycystic ovarian syndrome.
Methods: Patients were allocated randomly into 2 groups: Group I: 30 women received 50.000 Iu of oral vitamin D3 (Cholecalciferol) (Breva) once weekly for (12) weeks. Group II (placebo group): 30 women received placebo capsules once weekly for (12) weeks. Trans-abdominal US and transvaginal US examination were performed for detailed ovary imaging
Results: The difference in the glucose tolerance profile after treatment. There was a statistically significant difference between both groups regarding the mean fasting blood sugar levels (p =0.001), where the mean FBS in the intervention group was (79.60±9.464), while that of the placebo group was (89.67±9.181). Moreover, the HOMA-IR level varied significantly (p=0.017), where in the intervention group the mean level was (2.99±0.621), compared to a mean of (3.59±1.179) in the placebo group., none of the mean hormonal levels varied significantly among the intervention group from before to after treatment, except for the mean 25- hydroxy-vitamin D level (p= <0.001), which increased from (13.26±7.203) before treatment, to (26.76±15.531) after treatment.
Conclusion: In conclusion, Vitamin D supplementation in an oral dose of 50.000 IU of vitamin D3 (Cholecalciferol) once weekly for (12) weeks among women with PCOS significantly increased serum 25OHD levels, and significantly decrease insulin resistance and visceral fat thickness no potential effect was detected on BMI, waist circumference (WC)and waist to hip Ratio.